Innovative solution for chemotherapy-induced hair loss

How the gel works

The gel, tested in animal models and published in Biomaterials Advances, uses a hydrogel base to deliver vasoconstrictor drugs directly to the scalp. These drugs constrict blood vessels, thereby limiting the amount of chemotherapy drugs that reach the hair follicles.

Alternative to cooling caps

Currently, the only approved method to reduce chemotherapy-related hair loss is through cooling caps. However, these are expensive and often come with uncomfortable side effects. The new gel provides a more accessible and potentially safer alternative.

Drug delivery and hair follicle protection

The hydrogel absorbs large amounts of water and is formulated to slowly release lidocaine and adrenaline. These agents help minimize damage to the hair follicles, leading to what researchers describe as a “dramatic reduction” in hair loss.

Temperature-responsive design

One of the gel’s practical innovations is its temperature sensitivity. At body temperature, it thickens to adhere to the scalp; when cooled, it thins out, making it easy to rinse off.

Motivation behind the research

Bryan Smith, Associate Professor of Biomedical Engineering at Michigan State University, led the research. He noted that the development was inspired by conversations with cancer patients and healthcare providers, highlighting the urgent need for better solutions to manage hair loss during chemotherapy.